13C-labeled mixed triglyceride breath test (13C MTG-BT) in healthy children and children with cystic fibrosis (CF) under pancreatic enzyme replacement therapy (PERT): a pilot study.
The MTG-BT estimates the hydrolysis of triacyl-glycerols by pancreatic lipase, and appears attractive for monitoring exogenous lipase requirements in patients with exocrine pancreatic insufficiency. To assess the test's discrimination capacity and repeatability, 9 CF patients with PERT and 10 healthy children underwent the (13)C-MTG-BT twice, at a 2- to 4-week interval. The test distinguished well between patients with severe exocrine pancreatic insufficiency (SEPI) and healthy subjects. However, within-subject variability for postprandial per thousand(13)C-enrichment and postprandial % dose recovery (PDR) was high in both groups. Therefore, the (13)C-MTG-BT seems useful to distinguish between SEPI and normal exocrine pancreatic function, but requires further development to improve its repeatability.
Herzog
Denise C
DC
Divisions of Gastroenterology and Nutrition, CHU Ste-Justine, 3175 Côte Sainte-Catherine, Montreal, Quebec, Canada H3T 1C5. denise.herzog@umontreal.ca
Delvin
Edgard E
EE
Albert
Caroline
C
Marcotte
Jacques E
JE
Pelletier
Véronique A
VA
Seidman
Ernest G
EG
D000293:Adolescent; D001944:Breath Tests / Q000379:methods*; D002648:Child; D003550:Cystic Fibrosis / Q000201:enzymology / Q000628:therapy; D005260:Female; D006801:Humans; D008049:Lipase / Q000378:metabolism*; D008297:Male; D010179:Pancreas / Q000201:enzymology*; D010865:Pilot Projects; D015203:Reproducibility of Results; D014280:Triglycerides / Q000737:chemistry / Q000378:metabolism
D014280:Triglycerides; D008049:Lipase